Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.
Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback